Showing results (321-330 of 536) with videos related to

Sort By:
Pageof 54
Arteriosclerosis, Thrombosis, and Vascular Biology|February 28, 2004
Imatinib attenuates diabetes-associated atherosclerosisMarkus Lassila, Terri J Allen, Zemin Cao, et al.
Kidney International|January 12, 2002
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 ratsDarren J Kelly, Alison J Cox, Mary Tolcos, et al.
Diabetes|February 1, 2008
ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetesChris Tikellis, Katarzyna Bialkowski, Josepha Pete, et al.
The Journal of Biological Chemistry|February 24, 2007
Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathwaysYugang Tu, Weiping Wu, Tieqiao Wu, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 25, 2006
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouseAnna C Calkin, Sara Giunti, Karin A Jandeleit-Dahm, et al.
Hypertension (Dallas, Tex. : 1979)|June 1, 2012
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouseChris Tikellis, Raelene J Pickering, Despina Tsorotes, et al.
Diabetes|May 10, 2014
Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetesChris Tikellis, Raelene J Pickering, Despina Tsorotes, et al.
Kidney Medicine|February 29, 2024
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME TrialSamy Hadjadj, Mark E Cooper, Dominik Steubl, et al.
Circulation|March 17, 2004
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosisRiccardo Candido, Terri J Allen, Markus Lassila, et al.
Diabetes, Obesity & Metabolism|February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trialMark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.
Pageof 54